CME Ebitda from 2010 to 2024

CME Stock  USD 207.65  0.35  0.17%   
CME's EBITDA is increasing over the years with slightly volatile fluctuation. EBITDA is expected to dwindle to about 1.9 B. During the period from 2010 to 2024 CME EBITDA annual values regression line had geometric mean of  1,772,187,008 and mean square error of 362584.6 T. View All Fundamentals
 
EBITDA  
First Reported
2001-06-30
Previous Quarter
949.5 M
Current Value
B
Quarterly Volatility
264.7 M
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check CME financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among CME main balance sheet or income statement drivers, such as Depreciation And Amortization of 370.2 M, Interest Expense of 107.7 M or Selling And Marketing Expenses of 171 M, as well as many exotic indicators such as Price To Sales Ratio of 8.04, Dividend Yield of 0.0237 or PTB Ratio of 3.8. CME financial statements analysis is a perfect complement when working with CME Valuation or Volatility modules.
  
This module can also supplement CME's financial leverage analysis and stock options assessment as well as various CME Technical models . Check out the analysis of CME Correlation against competitors.

Latest CME's Ebitda Growth Pattern

Below is the plot of the Ebitda of CME Group over the last few years. It is CME's EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in CME's overall financial position and show how it may be relating to other accounts over time.
Ebitda10 Years Trend
Slightly volatile
   Ebitda   
       Timeline  

CME Ebitda Regression Statistics

Arithmetic Mean2,296,666,354
Geometric Mean1,772,187,008
Coefficient Of Variation36.55
Mean Deviation583,862,556
Median2,331,900,000
Standard Deviation839,526,433
Sample Variance704804.6T
Range3.8B
R-Value0.72
Mean Square Error362584.6T
R-Squared0.52
Significance0
Slope135,668,511
Total Sum of Squares9867264.8T

CME Ebitda History

20241.9 B
20233.8 B
20223.2 B
20212.8 B
20202.8 B
20192.7 B
20182.7 B

About CME Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include CME income statement, its balance sheet, and the statement of cash flows. CME investors use historical funamental indicators, such as CME's Ebitda, to determine how well the company is positioned to perform in the future. Although CME investors may use each financial statement separately, they are all related. The changes in CME's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on CME's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on CME Financial Statements. Understanding these patterns can help to make the right decision on long term investment in CME. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
EBITDA3.8 B1.9 B

Pair Trading with CME

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if CME position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CME will appreciate offsetting losses from the drop in the long position's value.

Moving together with CME Stock

  0.72ICE Intercontinental ExchangePairCorr

Moving against CME Stock

  0.48DHIL Diamond Hill InvestmentPairCorr
The ability to find closely correlated positions to CME could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace CME when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back CME - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling CME Group to buy it.
The correlation of CME is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as CME moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if CME Group moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for CME can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether CME Group is a strong investment it is important to analyze CME's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact CME's future performance. For an informed investment choice regarding CME Stock, refer to the following important reports:
Check out the analysis of CME Correlation against competitors.
You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.

Complementary Tools for CME Stock analysis

When running CME's price analysis, check to measure CME's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CME is operating at the current time. Most of CME's value examination focuses on studying past and present price action to predict the probability of CME's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CME's price. Additionally, you may evaluate how the addition of CME to your portfolios can decrease your overall portfolio volatility.
Fundamental Analysis
View fundamental data based on most recent published financial statements
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Commodity Directory
Find actively traded commodities issued by global exchanges
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Is CME's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CME. If investors know CME will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CME listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.03)
Dividend Share
4.45
Earnings Share
8.8
Revenue Per Share
15.638
Quarterly Revenue Growth
0.032
The market value of CME Group is measured differently than its book value, which is the value of CME that is recorded on the company's balance sheet. Investors also form their own opinion of CME's value that differs from its market value or its book value, called intrinsic value, which is CME's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CME's market value can be influenced by many factors that don't directly affect CME's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CME's value and its price as these two are different measures arrived at by different means. Investors typically determine if CME is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CME's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.